While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...
The Motley Fool on MSN2d
2 Hot Biopharma Stocks to Buy and Hold for 5 YearsSummit Therapeutics (NASDAQ: SMMT) is a biotech stock that few investors have heard of, but it has the makings of a winner ...
Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
(See BOOT stock forecast) Next on the list is Summit Therapeutics, a clinical-stage biopharma company that has brought a ...
Ivonescimab achieves hazard ratio of 0.51, beating pembrolizumab in progression-free survival. Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034.
He pointed specifically to encouraging phase 3 trial results for ivonescimab, the cancer treatment it licensed in 2023, in the treatment of lung cancer in a study conducted in China. Although some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback